Adagene Inc. (ADAG)
3.94
+0.41 (11.61%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13D/A Adagene Inc. Filed by: Luo Peter
June 8, 2026 6:23 AM - SEC Filing
Form SCHEDULE 13G/A Adagene Inc. Filed by: WuXi PharmaTech Healthcare Fund I L.P.
May 15, 2026 4:32 PM - SEC Filing
Adagene to Participate in Two Upcoming Investor Conferences
May 12, 2026 8:30 AM - Globe NewsWire
Form SCHEDULE 13G Adagene Inc. Filed by: JANUS HENDERSON GROUP PLC
May 7, 2026 11:30 AM - SEC Filing
Adagene presents trial data showing muzastotug combination benefits
April 17, 2026 4:01 PM - StreetInsider
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
April 17, 2026 4:01 PM - StreetInsider
Form 6-K Adagene Inc. For: Apr 17
April 17, 2026 4:00 PM - SEC Filing
Adagene adds Peter Lebowitz to scientific advisory board
April 14, 2026 7:01 AM - StreetInsider
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
April 14, 2026 7:00 AM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Adagene Inc (ADAG)
April 7, 2026 7:49 AM - StreetInsider
Adagene Inc (ADAG) PT Raised to $10 at Guggenheim
April 6, 2026 6:38 AM - StreetInsider
Form 424B5 Adagene Inc.
April 2, 2026 4:26 PM - SEC Filing
Adagene Inc (ADAG) PT Raised to $8 at Leerink Partners
April 2, 2026 2:53 PM - StreetInsider
Form 6-K Adagene Inc. For: Apr 02
April 2, 2026 7:12 AM - SEC Filing
Adagene prices $70 million public offering at $3.75 per ADS
April 2, 2026 7:10 AM - StreetInsider
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
April 2, 2026 7:10 AM - StreetInsider
Adagene partners with Incyte for cancer drug combination study
April 2, 2026 7:01 AM - StreetInsider
Form 424B5 Adagene Inc.
April 2, 2026 7:01 AM - SEC Filing
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable
April 2, 2026 7:01 AM - StreetInsider
Form 6-K Adagene Inc. For: Apr 02
April 2, 2026 7:00 AM - SEC Filing
Adagene reports higher response rates with increased muzastotug dosing
April 2, 2026 7:00 AM - StreetInsider
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Re
April 2, 2026 7:00 AM - StreetInsider
Form 6-K Adagene Inc. For: Apr 01
April 1, 2026 5:16 PM - SEC Filing
Form 20-F Adagene Inc. For: Dec 31
April 1, 2026 5:16 PM - SEC Filing
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
April 1, 2026 5:00 PM - StreetInsider
Full Article List
